Incomplete and atypical Kawasaki disease in a young infant: Severe, recalcitrant disease responsive to infliximab

Clinical Pediatrics

Volumn 46, Issue 4, 2007, Pages 345-348

  O'Connor, Matthew J ^a   Saulsbury, Frank T ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Atypical Kawasaki disease; Infliximab; Peripheral gangrene

Indexed keywords

ACETYLSALICYLIC ACID; GLYCERYL TRINITRATE; HEPARIN; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; PREDNISOLONE; WARFARIN;

ACUTE DISEASE; ARTICLE; CASE REPORT; CORONARY ARTERY ANEURYSM; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEVER; GANGRENE; HUMAN; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; RELAPSE; TREATMENT RESPONSE; VASCULITIS;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ASPIRIN; CORONARY ANEURYSM; GANGRENE; HEPARIN; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; MALE; METHYLPREDNISOLONE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PLATELET AGGREGATION INHIBITORS;

EID: 34247216142     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/0009922806294842     Document Type: Article

References (26)

1. Newburger JW, Takahashi M., Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986 ; 315: 341-347.
2. Newburger JW, Takahashi M., Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991 ; 324: 1633-1639.
3. Sundel RP, Burns JC, Baker A., Beiser AS, Newburger JW Gamma globulin re-treatment in Kawasaki disease. J Pediatr. 1993 ; 123: 657-659.
4. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J. 1998 ; 17: 1144-1148.
5. Newburger JW, Takahashi M., Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease. Circulation. 2004 ; l10: 2747-2771.
6. Taubert KA, Rowley AH, Shulman ST Seven-year national survey of Kawasaki disease and rheumatic fever. Pediatr Infect Dis J. 1994 ; 13: 704-708.
7. Burns JC, Wiggins JW, Toews WH, et al. Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. J Pediatr. 1986 ; 109: 759-763.
8. Rosenfeld EA, Corydon KE, Shulman ST Kawasaki disease in infants less than one year of age. J Pediatr. 1995 ; 126: 524-529.
9. Tsuchida S., Yamanaka T., Tsuchida R., Nakamura Y., Yashiro M., Yanagawa H. Epidemiology of infant Kawasaki disease with a report of the youngest neonatal case ever reported in Japan. Acta Paediatr. 1996 ; 85: 995-997.
10. Hara T., Mizuno Y., Akeda H., et al. Thrombocytopenia: a complication of Kawasaki disease. Eur J Pediatr. 1988 ; 147: 51-53.
11. Tomita S., Chung K., Mas M., Gidding S., Shulman ST Peripheral gangrene associated with Kawasaki disease. Clin Infect Dis. 1992 ; 14: 121-126.
12. Chang JS, Lin JS, Peng CT, Tsai CH Kawasaki disease complicated by peripheral gangrene. Pediatr Cardiol. 1999 ; 20: 139-142.
13. Durall AL, Phillips JR, Weisse ME, Mullett CJ Infantile Kawasaki disease and peripheral gangrene. J Pediatr. 2006 ; 149: 131-133.
14. Fukunishi M., Kikkawa M., Hamana K., et al. Prediction of non-responsiveness to intravenous high-dose gamma globulin therapy in patients with Kawasaki disease at onset. J Pediatr. 2000 ; 137: 172-176.
15. Durongpisitkul K., Soongswang J., Laohaprasitiporn D., Nana A., Prachuabmoh C., Kangkagate C. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol. 2003 ; 24: 145-148.
16. Wright DA, Newburger JW, Baker A., Sundel RP Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr. 1996 ; 128: 146-149.
17. Dale RC, Saleem MA, Daw S., Dillon MJ Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. J Pediatr. 2000 ; 137: 723-726.
18. Takeshita S., Kawamura Y., Nakatani K., Tsujimoto H., Tokutomi T. Standard-dose and short-term corticosteroid therapy in immunoglobulin-resistant Kawasaki disease. Clin Pediatr. 2005 ; 44: 423-426.
19. Knight DM, Trinh H., Le J., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993 ; 30: 1443-1453.
20. Maury CP, Salo E., Pelkonen P. Elevated circulating tumor necrosis factor-α in patients with Kawasaki disease. J Lab Clin Med. 1989 ; 113: 651-654.
21. Matsubara T., Furukawa S., Yabatu K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol. 1990 ; 56: 29-36.
22. Weiss JE, Eberhard A., Chowdhury D., Gotlieb BS Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol. 2004 ; 31: 808-810.
23. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005 ; 146: 662-667.
24. Shinohara M., Sone K., Tomomasa T., Morikawa A. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr. 1999 ; 135: 465-469.
25. Sundel RP, Baker A., Fulton DR, Newburger JW Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr. 2003 ; 142: 611-616.
26. Wooditch AS, Aronoff SC Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children. Pediatrics. 2005 ; 116: 989-995.